Page last updated: 2024-11-13
decarbamylsaxitoxin
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
decarbamoylsaxitoxin : A pyrrolopurine that is 2,6-diiminodecahydropyrrolo[1,2-c]purine carrying an additional hydroxymethyl substituent at position 4 as well as two hydroxy substituents at position 10. A toxin that is isolated from marine dinoflagellates and cyanobacteria and is known to cause paralytic shellfish poisoning. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 21117969 |
| CHEMBL ID | 5205795 |
| CHEBI ID | 133919 |
| MeSH ID | M0107274 |
Synonyms (23)
| Synonym |
|---|
| dcstx-saxitoxin |
| 58911-04-9 |
| 4-(hydroxymethyl)-2,6-diimino-decahydropyrrolo[1,2-c]purine-10,10-diol |
| CHEBI:133919 |
| (3as,4r,10as)-2,6-diamino-4-(hydroxymethyl)-3a,4,8,9-tetrahydro-1h,8h-pyrrolo[1,2-c]purine-10,10-diol |
| decarbamoylsaxitoxin |
| decarbamylsaxitoxin |
| C20021 |
| ec89au638s , |
| unii-ec89au638s |
| 1h,10h-pyrrolo(1,2-c)purine-10,10-diol, 2,6-diamino-3a,4,8,9-tetrahydro-4-(hydroxymethyl)-, (3as-(3aalpha,4alpha,10ar*))- |
| 1h,10h-pyrrolo(1,2-c)purine-10,10-diol, 2,6-diamino-3a,4,8,9-tetrahydro-4-(hydroxymethyl)-, (3as,4r,10as)- |
| DTXSID70207660 |
| (+)-decarbamylsaxitoxin |
| (3as,4r,10as)-2,6-diamino-3a,4,8,9-tetrahydro-4-(hydroxymethyl)-1h,10h-pyrrolo(1,2-c)purine-10,10-diol |
| decarbamoylstx |
| 1h,10h-pyrrolo(1,2-c)purine-10,10-diol, 2,6-diamino-3a,4,8,9-tetrahydro-4-(hydroxymethyl)-, (3as-(3a.alpha.,4.alpha.,10ar*))- |
| CHEMBL5205795 , |
| (3as,4r,10as)-2,6-diamino-4-(hydroxymethyl)-3a,4,8,9-tetrahydro-3h,10h-pyrrolo[1,2-c]purine-10,10-diol |
| (3as,4r,10as)-2,6-diamino-4-(hydroxymethyl)-3a,4,8,9-tetrahydro-1h-pyrrolo[1,2-c]purine-10,10-diol |
| Q27277104 |
| bdbm50595856 |
| AKOS040751507 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Roles (5)
| Role | Description |
|---|---|
| marine metabolite | Any metabolite produced during a metabolic reaction in marine macro- and microorganisms. |
| neurotoxin | A poison that interferes with the functions of the nervous system. |
| toxin | Poisonous substance produced by a biological organism such as a microbe, animal or plant. |
| bacterial metabolite | Any prokaryotic metabolite produced during a metabolic reaction in bacteria. |
| xenobiotic | A xenobiotic (Greek, xenos "foreign"; bios "life") is a compound that is foreign to a living organism. Principal xenobiotics include: drugs, carcinogens and various compounds that have been introduced into the environment by artificial means. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Drug Classes (6)
| Class | Description |
|---|---|
| pyrrolopurine | Any organic heterotricyclic compound with a skeleton consisting of a pyrrole ring fused to a purine ring system. |
| guanidines | Any organonitrogen compound containing a carbamimidamido (guanidino) group. Guanidines have the general structure (R(1)R(2)N)(R(3)R(4)N)C=N-R(5) and are related structurally to amidines and ureas. |
| ketone hydrate | A 1,1-diol resulting from the formal addition of water to the carbonyl group of a ketone. |
| primary alcohol | A primary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has either three hydrogen atoms attached to it or only one other carbon atom and two hydrogen atoms attached to it. |
| alkaloid | Any of the naturally occurring, basic nitrogen compounds (mostly heterocyclic) occurring mostly in the plant kingdom, but also found in bacteria, fungi, and animals. By extension, certain neutral compounds biogenetically related to basic alkaloids are also classed as alkaloids. Amino acids, peptides, proteins, nucleotides, nucleic acids, amino sugars and antibiotics are not normally regarded as alkaloids. Compounds in which the nitrogen is exocyclic (dopamine, mescaline, serotonin, etc.) are usually classed as amines rather than alkaloids. |
| paralytic shellfish toxin | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Protein Targets (2)
Inhibition Measurements
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Sodium channel protein type 4 subunit alpha | Homo sapiens (human) | IC50 (µMol) | 0.0320 | 0.0001 | 3.5075 | 10.0000 | AID1875797 |
| Sodium channel protein type 9 subunit alpha | Homo sapiens (human) | IC50 (µMol) | 0.1500 | 0.0060 | 2.7749 | 9.0000 | AID1875796 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Biological Processes (13)
Molecular Functions (2)
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| voltage-gated sodium channel activity | Sodium channel protein type 4 subunit alpha | Homo sapiens (human) |
| protein binding | Sodium channel protein type 4 subunit alpha | Homo sapiens (human) |
| voltage-gated sodium channel activity | Sodium channel protein type 9 subunit alpha | Homo sapiens (human) |
| protein binding | Sodium channel protein type 9 subunit alpha | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
Ceullar Components (3)
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| plasma membrane | Sodium channel protein type 4 subunit alpha | Homo sapiens (human) |
| voltage-gated sodium channel complex | Sodium channel protein type 4 subunit alpha | Homo sapiens (human) |
| plasma membrane | Sodium channel protein type 9 subunit alpha | Homo sapiens (human) |
| axon | Sodium channel protein type 9 subunit alpha | Homo sapiens (human) |
| voltage-gated sodium channel complex | Sodium channel protein type 9 subunit alpha | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
Bioassays (3)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1875797 | Inhibition of human Nav1.4 expressed in HEK293 cells by whole cell patch clamp electrophysiology recording | 2022 | ACS medicinal chemistry letters, Nov-10, Volume: 13, Issue:11 | Discovery of Selective Inhibitors of Na |
| AID1875796 | Inhibition of human Nav1.7 expressed in HEK293 cells by whole cell patch clamp electrophysiology recording | 2022 | ACS medicinal chemistry letters, Nov-10, Volume: 13, Issue:11 | Discovery of Selective Inhibitors of Na |
| AID1875798 | Selectivity index, ratio of IC50 for inhibition of human Nav1.4 expressed in HEK293 cells to IC50 for inhibition of human Nav1.7 expressed in HEK293 cells by whole cell patch clamp electrophysiology recording | 2022 | ACS medicinal chemistry letters, Nov-10, Volume: 13, Issue:11 | Discovery of Selective Inhibitors of Na |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (20)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (5.00) | 18.7374 |
| 1990's | 5 (25.00) | 18.2507 |
| 2000's | 6 (30.00) | 29.6817 |
| 2010's | 7 (35.00) | 24.3611 |
| 2020's | 1 (5.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.01
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.01) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 23 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||